Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 25, 2025Frontiers in OncologyOpen Access

XPO1-inhibitor Selinexor induces MGMT expression by activating PKA-CREB signaling in IDH wildtype glioblastoma

View Full Paper
Ask AI
Bookmark
Share

Authors

JMJosephine A. MapundaYSYuta SuzukiDBDanielle M. Burgenske

Discussion

Loading...

Member takes

Overview

Genome-wide screening revealed that XPO1 inhibition by Selinexor enhances TMZ sensitivity in glioblastoma, indicating a role for MGMT expression.

Key Points

  • Selinexor treatment enhances sensitivity to TMZ in MGMT-methylated glioblastoma cells, suggesting a therapeutic strategy.
  • MGMT expression status significantly influences the effectiveness of combined Selinexor/TMZ treatment in glioblastoma models.
  • PKA-CREB signaling pathway is crucial for the Selinexor-induced increase in MGMT expression, highlighting potential targets for therapy.
  • Exportin 1 (XPO1) plays a key role in mediating resistance mechanisms in MGMT-methylated glioblastoma cells, which could inform future treatments.

Cite This Study

Mapunda et al. (2025) studied this question.

synapsesocial.com/papers/68d5bd6edc445aa9033b0a11https://doi.org/10.3389/fonc.2025.1633580
View Full Paper
Ask AI
Bookmark
Share